Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations
Disease area: Respiratory critical care



Rating:

Share or cite this content

Citations should be made in the following way:
G. Choudhury, J. Chalmers, A. Hill (United Kingdom). 7-day course of antibiotics had similar efficacy to prolonged course in severe community-acquired pneumonia: a propensity-adjusted analysis. Eur Respir J 2010; 36: Suppl. 54, 3010

Member's Comments

No comment yet.

Related content which might interest you: Effect of corticoids on the clinical course and outcome of severe community-acquired pneumonia Source: Annual Congress 2004 - SARS and other lower respiratory tract infections Year: 2004 How often can we use short course therapy in patients with hospital-acquired pneumonia? Source: Eur Respir J 2007; 30: Suppl. 51, 408s Year: 2007 Comparison of different models of azithromycin treatment of patients with no severe community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 166s Year: 2006 5-day moxifloxacin versus 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis: a cost-minimization analysis Source: Eur Respir J 2003; 22: Suppl. 45, 336s Year: 2003 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients Source: Eur Respir J 2015; 45: 463-472 Year: 2015 The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis Source: Eur Respir J 2007; 30: 525-531 Year: 2007 Changes in empirical initial antibiotic therapy in community-acquired pneumonia: assessment of clinical failure versus discordant therapy Source: Eur Respir J 2006; 28: Suppl. 50, 736s Year: 2006 The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 733s Year: 2006 Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis Source: Eur Respir J 2012; 39: 611-618 Year: 2012 Low-dose corticosteroids during severe community-acquired pneumonia: end of the story Source: Eur Respir J 2015; 45: 305-307 Year: 2015 Efficacy and safety of stepwise therapy in patients with community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 377s Year: 2006 Are corticosteroids useful in community-acquired pneumonia? Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 The use of piperacillin/tazobactam for treatment of pneumonia in neutropenic patients Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010 Costs of treatment of hospitalised community-acquired pneumonia from the hospitals’ perspective – a prospective study comparing moxifloxacin with other antibiotic treatment alternatives Source: Eur Respir J 2004; 24: Suppl. 48, 185s Year: 2004 Impact of reducing antibiotic treatment on inflammation among patients with community-acquired pneumonia. Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia Year: 2019 Comparison of treatment outcomes in community-acquired pneumonia patients treated with beta lactam-macrolide combination versus fluoroquinolone monotherapy Source: Annual Congress 2012 - Management of severe respiratory infections Year: 2012 A simple method for determining the time of conversion to oral antibiotic therapy in community-acquired pneumonia (CAP) Source: Eur Respir J 2001; 18: Suppl. 33, 503s Year: 2001 The main risk factors of the community-acquired pneumonia delayed course Source: Eur Respir J 2005; 26: Suppl. 49, 643s Year: 2005